Japan Surrogacy Contracts, Clinics, Agencies and Payments: Legal Risks
Short answer and scope
Japan should not be treated as a jurisdiction where a clinic, agency or signed surrogacy agreement can promise a predictable legal result. The key questions are separate: whether a particular medical service may be provided, whether each contract and payment is enforceable, who is legally recognised as the child’s parent, and whether Japanese authorities will accept documents issued abroad. The official sources do not establish a comprehensive, dedicated statutory scheme setting out a full set of rules for surrogacy contracts, agency fees and clinic involvement. That limited finding is not proof that every arrangement is permitted, nor a certification that no other law applies. General civil-law rules, medical regulation, professional standards, privacy rules and foreign law may matter depending on who does what and where. Before committing funds, parties should obtain advice on the actual documents and intended route, not rely on a brochure, a clinic’s marketing or an agency’s promise.
The Japanese legal framework
The Act on Assisted Reproductive Technology Offering and the Special Provisions of the Civil Code Related to Parent-Child Relationships (Act No. 76 of 2020) defines assisted reproductive technology to include artificial insemination, in-vitro fertilisation and embryo transfer. Its principles include appropriate treatment, protection of the health of the woman who becomes pregnant and gives birth, and adequate explanation and informed understanding by the parties. Article 9 provides that, where a woman conceives and gives birth through ART using another woman’s ovum or an embryo derived from it, the woman who gives birth is the child’s mother. The relevant parentage provisions took effect on 11 December 2021 and apply to children born on or after that date. Article 9 is specifically worded for ART using another woman’s ovum (including an embryo derived from it). If the woman who gives birth uses her own ovum, that specific condition is not met on the face of Article 9; parentage must instead be assessed under the other applicable rules, rather than treating Article 9 as directly determinative. The Act does not supply a complete model contract, a universal agency-licensing scheme, or a comprehensive tariff and refund code for surrogacy. Civil Code Article 90 separately states that a juridical act contrary to public policy is void. That general rule makes the wording and circumstances important; it does not, by itself, establish that every surrogacy agreement or every payment is automatically invalid.
What the Supreme Court decision means
The Supreme Court’s decision of 23 March 2007, case 2006 (Kyo) No. 47, remains an important warning about cross-border assumptions. A Japanese couple had used their own gametes and a surrogate in Nevada, obtained a Nevada order identifying them as the children’s parents, and then sought Japanese registration. The Supreme Court held that the foreign judgment in that case was not effective in Japan because it conflicted with the Japanese rules for establishing a natural parent-child relationship; the Court also discussed the principle that the woman who gives birth is the mother. The judgment preceded Act No. 76 of 2020, so it must be read together with the later statute and the exact facts of any present case. It is not safe to say that every foreign order will always be rejected, but it is equally unsafe to assume that a foreign birth certificate, court order, DNA connection or contract will automatically determine parentage in Japan. Have Japanese counsel assess the actual document, its finality, the relevant law and the route to registration or any other lawful procedure.
What a contract can and cannot do
A contract can allocate responsibilities between its signatories, but it cannot simply rewrite Japanese parentage rules or bind a public registrar that is not a party to it. A clause promising that intended parents will automatically be treated as legal parents is therefore not a substitute for a separate parentage analysis. Likewise, a foreign choice-of-law, court-jurisdiction or arbitration clause may help organise a contractual dispute, but it does not guarantee recognition of parentage or acceptance of a foreign document in Japan. Enforceability must be assessed clause by clause, considering the governing law, public policy, the identities and consent of the parties, the place of treatment and any mandatory rules. Particular scrutiny is needed for clauses that purport to control medical decisions, require a party to surrender rights regardless of circumstances, impose disproportionate penalties, or make payment conditional on delivery of a child or on a specified medical outcome. Do not assume a clause is valid because it appears in a professionally drafted document, or void merely because it relates to surrogacy; obtain a reasoned opinion on the actual wording and facts.
Clinics and agencies: verify the actual role
Treat the clinic and the agency as different service providers with different responsibilities. A clinic should identify the legal entity providing treatment, the treating clinicians, the procedures offered, the consent process, record-keeping arrangements, complication protocols and the jurisdiction in which the medical work will occur. Verify professional and facility authorisations with the competent authority where required; do not rely only on a website logo or a certificate supplied by the intermediary. An agency should identify the contracting entity, its actual role, all subcontractors, the services it does not provide, and whether it receives or holds money for other parties. Ask whether the agency merely introduces parties, coordinates logistics, gives legal information, arranges medical treatment or handles funds. Those activities are not interchangeable, and a company registration does not establish that the entity is authorised to provide medical or legal services. The sources do not establish one universal Japanese surrogacy-agency licence or a blanket approval for all intermediary models. Confirm requirements separately in Japan and in each country where the agency, clinic, surrogate or intended parents act.
A separate layer is professional self-regulation. The Japan Society of Obstetrics and Gynecology (JSOG) states in its 2023 gynecology guideline that surrogacy is not accepted under the Society’s view. JSOG-hosted material from 2022 explains that these views are voluntary professional rules, not legislation: the Society asks its members to follow them and may take action under its bylaws, while the views do not bind non-members as such. This is not the same as a universal statutory ban, and it does not resolve what any particular clinic is legally permitted to do. Before relying on a clinic’s offer, ask whether its clinicians are JSOG members, which professional and institutional rules apply, and whether the position has changed. Obtain independent advice in Japan and in every country where treatment or intermediation will occur.
Payments: classify every transfer
Do not treat the word “compensation” as a complete legal analysis. Separate any amount intended for the surrogate from documented pregnancy-related expenses, clinic charges, agency fees, legal advice, insurance, travel and post-birth administration. The sources do not establish a universal Japanese compensation cap, blanket permission for commercial surrogacy payments, or a blanket prohibition on every payment. That uncertainty must not be converted into an assurance that a particular payment is lawful. The legal character of a transfer may depend on its purpose, recipient, timing, contractual structure, place of performance and applicable foreign law; other general rules may also apply. Before paying, require an itemised budget, named payees, invoices or receipts, clear payment milestones, a defined escrow holder if any, rules for unused funds, and written treatment of failed transfers, miscarriage, medical complications, cancellation, agency default and disagreement. Confirm the currency, bank charges, tax responsibilities and who bears exchange-rate changes. Do not send a large non-refundable sum merely because an agency says that payment is customary or urgent.
One legislative proposal deserves separate treatment. The 2025 Bill on Specified Assisted Reproductive Technology proposed prohibiting financial benefits given or received as consideration for surrogate pregnancy and childbirth carried out through “specified ART” as the bill defines it, and remuneration for brokering such arrangements. The bill defines “specified ART” by reference to sperm or ova from outside the intending couple; therefore, its proposed surrogacy-payment provisions should not be assumed to cover arrangements using only the intended parents’ own gametes. As of 24 October 2026, the official parliamentary record shows deliberation unfinished in the 217th Diet session and no promulgation date or law number. These proposed clauses are not enacted law on that record. The record does not rule out a later, separate measure, so recheck current legislation before signing or paying.
Clauses requiring close review
The most important clauses are those dealing with consent, medical autonomy, risk and the possibility that the hoped-for outcome does not occur. The agreement should describe the services actually promised and distinguish them from outcomes no provider can guarantee. It should state who pays for consultations, medication, travel, pregnancy-related expenses, complications, delivery and post-partum care, and how changes require written agreement. It should specify how records are kept and shared, who may access medical information, how confidential data are protected, and what happens if a party withdraws consent or a provider becomes unavailable. It should address dispute notice, negotiation, urgent medical decisions, applicable law, forum, language and reliable service of notices. Avoid terms that purport to force a surrogate to undergo a procedure, dictate whether a pregnancy must be terminated or continued, or penalise a person for exercising medical consent. Japanese law’s ART principles emphasise health protection and informed understanding; the 2007 case also described the significance of safeguards in the particular foreign contract before the Court. These sources do not settle every clause’s consequence, so the exact text and the law governing treatment require individual review.
Documents to obtain before signing
Before signature, assemble a single due-diligence file. It should include the full draft contract and every schedule; legal names, addresses and registration details of all contracting entities; the clinic’s identity and clinician details; evidence of any licence or authorisation required in the relevant place; the agency’s written scope and subcontractor list; an itemised cost estimate; proposed payment instructions and refund terms; insurance information; consent forms; privacy and records policies; and the proposed medical and dispute procedures. Obtain independent legal advice for the surrogate and the intended parents, rather than assuming one agency lawyer represents everyone’s interests. Ask for the legal basis and practical steps for parentage, birth registration and any post-birth procedure in Japan and the place of birth. A general statement such as “our lawyer handles everything” is not a substitute for identifying the authority, application, documents, expected decision and unresolved risks. Confirm that any translated version matches the controlling version and that every party understands the same text. Do not sign blank schedules or allow material payment terms to remain in informal messages only.
If something goes wrong
If a dispute develops, first identify what is actually contested: medical care, a payment, agency performance, contract termination, access to records, parentage or the recognition of a foreign decision. These are different issues and may require different procedures. Preserve the signed agreement and all versions, annexes, invoices, bank records, receipts, medical records, consent forms, messages, emails, advertisements and representations made before payment. Record dates and keep originals; do not alter messages or rely only on screenshots when full exports are available. Ask counsel to assess the governing law, limitation periods, urgent protective steps and the correct court, regulator or professional body. A contract dispute does not itself determine who the child’s legal parent is. Conversely, a parentage problem may not be solved by winning a claim for a refund. Do not publish identifiable medical or family information to pressure a counterparty; privacy and the child’s interests need separate protection. If a foreign clinic or agency is involved, obtain advice in that jurisdiction as well as Japanese advice, and coordinate the analysis without assuming one country’s decision controls the other.
A safer decision sequence
A prudent sequence is: (1) describe the intended arrangement, including the location of every medical step and the role of each participant; (2) obtain a written Japanese-law assessment of the proposed contract, payments and parentage pathway; (3) verify the clinic, agency and any subcontractors with the relevant authorities; (4) review the full itemised budget, escrow and refund triggers; (5) give each participant independent advice and a genuine opportunity to understand and consent; (6) sign only the final, consistent versions and retain complete copies; and (7) reassess the plan before each major payment, embryo transfer, birth and registration step if the facts or law change. If the provider will not disclose its legal identity, refuses independent advice, guarantees parentage without explaining the legal route, demands unexplained cash or crypto payments, or pressures someone to waive medical choices, pause the transaction. These are practical red flags, not automatic findings of illegality. A tailored opinion should answer what is lawful, what remains uncertain, which clause or payment creates the risk, who can decide the disputed issue, and what documents or alternative arrangements are available.
Source limits and review status
The primary sources include the 2020 ART Act, the Japanese Civil Code’s public-policy rule, the Supreme Court’s 2007 decision and a 2003 Ministry of Health, Labour and Welfare committee report. The 2003 report recommended prohibition and proposed statutory restrictions; it is policy history, not itself an enacted criminal ban. The official legislative record for the 2025 Bill on Specified Assisted Reproductive Technology showed the bill’s deliberation as unfinished in the 217th Diet session; that record alone does not settle whether a later measure was introduced or enacted. In particular, counsel should verify the current effect of Act No. 76 on the precise family facts, the enforceability of each payment and intermediary arrangement, and the available registration or parentage procedure.
The sources concerning the 2025 bill and the JSOG position must be kept in their proper categories: the bill’s proposed payment and brokering restrictions are not enacted law on the cited record, and the JSOG position is professional self-regulation rather than a universal statutory ban. Neither source replaces a check for later legislation, the current Society position or the rules applicable to the specific clinic.
Primary sources and legal materials
- Supreme Court of Japan, decision of 23 March 2007, case 2006 (Kyo) No. 47 — Official judgment and case facts; the holding concerns the particular foreign parentage decision and Japanese law at the time.
- Act No. 76 of 2020 on assisted reproductive technology and parent-child relationships (official e-Gov text) — Official text; defines ART and sets principles and the specific parentage rule in Article 9.
- Civil Code of Japan, including Article 90 (official e-Gov text) — Official Japanese text; Article 90 states the public-policy invalidity rule.
- Ministry of Health, Labour and Welfare, 2003 committee report summary on assisted reproductive technology (policy material) — Official committee-report summary; recommendations and proposals, not themselves enacted legislation.
- House of Representatives, bill-status record: Bill on Specified Assisted Reproductive Technology, 217th Diet — Official parliamentary status record; the page records the 2025 bill as uncompleted in the 217th Diet session, not the status of any later measure.
- Japan Society of Obstetrics and Gynecology, Obstetrics and Gynecology Clinical Practice Guidelines—Gynecology Outpatient Care 2023, CQ317 — Records the Society’s position that surrogacy is not accepted; professional guidance, not legislation.
- Japan Society of Obstetrics and Gynecology, 2022 proposal on a public body for bioethics in reproductive and perinatal medicine — Describes the Society’s views as voluntary self-regulation, asks members to comply and distinguishes them from legislation.
- House of Representatives of Japan, Bill on Specified Assisted Reproductive Technology, Bill No. 1, 217th Diet — Proposed Articles 66(2)–(3) would prohibit consideration for surrogacy, and Articles 67(2)–(3) remuneration for brokering, within the bill’s defined “specified ART” scope (using gametes from outside the intending couple); proposal only, not enacted law.
